Scholarlink

<p>Chimeric antigen receptor (CAR)–T cell therapy has significantly improved outcomes in hematologic malignancies but remains constrained by complex ex vivo manufacturing and lymphodepleting chemotherapy. In vivo CAR-T therapy enables direct genetic programming of endogenous T cells through systemic delivery of CAR-encoding vectors, thereby bypassing ex vivo manipulation and simplifying treatment workflows. This strategy has the potential to reduce production timelines, lower costs, and broaden patient accessibility. In addition, in vivo CAR-T approaches may preserve more physiological T-cell states and offer improved scalability. Importantly, however, current in vivo CAR-T platforms differ substantially in delivery modality, persistence, reversibility, safety profile, and translational feasibility. Here, we summarize the latest advances in major preclinical approaches and early clinical studies presented at the 2025 ASH annual meeting, with emphasis on the comparative strengths, limitations, and translational trade-offs of viral vector-based, RNA/lipid nanoparticle-based, non-viral DNA, and gene-writing strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In vivo CAR-T therapy: latest updates from the 2025 ASH annual meeting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月22日

查看全文
  • Shule Wang,
  • Ran Kong,
  • Guangcai Zhong,
  • Xinyu Yang,
  • Xiangxiang Zhou

摘要

Chimeric antigen receptor (CAR)–T cell therapy has significantly improved outcomes in hematologic malignancies but remains constrained by complex ex vivo manufacturing and lymphodepleting chemotherapy. In vivo CAR-T therapy enables direct genetic programming of endogenous T cells through systemic delivery of CAR-encoding vectors, thereby bypassing ex vivo manipulation and simplifying treatment workflows. This strategy has the potential to reduce production timelines, lower costs, and broaden patient accessibility. In addition, in vivo CAR-T approaches may preserve more physiological T-cell states and offer improved scalability. Importantly, however, current in vivo CAR-T platforms differ substantially in delivery modality, persistence, reversibility, safety profile, and translational feasibility. Here, we summarize the latest advances in major preclinical approaches and early clinical studies presented at the 2025 ASH annual meeting, with emphasis on the comparative strengths, limitations, and translational trade-offs of viral vector-based, RNA/lipid nanoparticle-based, non-viral DNA, and gene-writing strategies.